Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
MD Anderson Cancer Center, Houston, TX, USA.
Cancer Med. 2020 Jul;9(13):4593-4602. doi: 10.1002/cam4.3039. Epub 2020 May 6.
Outcomes data regarding advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are limited, consisting primarily of retrospective series and post hoc analyses of clinical trials.
In this multi-center retrospective study, data were abstracted from the medical records of 350 patients from nine sarcoma centers throughout the United States and combined into a registry. Patients with advanced/unresectable or metastatic SS (n = 249) or MRCL (n = 101) who received first-line systemic anticancer therapy and had records of tumor imaging were included. Overall survival (OS), time to next treatment, time to distant metastasis, and progression-free survival (PFS) were evaluated using the Kaplan-Meier method and Cox regression.
At start of first-line systemic anticancer therapy, 92.4% of patients with SS and 91.1% of patients with MRCL had metastatic lesions. However, 74.7% of patients with SS and 72.3% of patients with MRCL had ≥2 lines of systemic therapy. Median OS and median PFS from first-line therapy for SS was 24.7 months (95% CI, 20.9-29.4) and 7.5 months, respectively (95% CI, 6.4-8.4). Median OS and median PFS from start of first-line therapy for MRCL was 29.9 months (95% CI, 27-44.6) and 8.9 months (95% CI 4.5-12.0).
To the best of our knowledge, this is the largest retrospective study of patients with SS and MRCL. It provides an analysis of real-world clinical outcomes among patients treated at major sarcoma cancer centers and could inform treatment decisions and design of clinical trials. In general, the survival outcomes for this selected population appear more favorable than in published literature.
关于高级滑膜肉瘤（SS）和黏液样/圆形细胞脂肪肉瘤（MRCL）的预后数据有限，主要由回顾性系列和临床试验的事后分析组成。
在这项多中心回顾性研究中，从美国 9 个肉瘤中心的 350 名患者的病历中提取数据，并将其组合成一个登记处。纳入接受一线系统抗癌治疗且有肿瘤影像学记录的晚期/不可切除或转移性 SS（n=249）或 MRCL（n=101）患者。使用 Kaplan-Meier 方法和 Cox 回归评估总生存期（OS）、下一次治疗时间、远处转移时间和无进展生存期（PFS）。
在开始一线系统抗癌治疗时，92.4%的 SS 患者和 91.1%的 MRCL 患者有转移病灶。然而，74.7%的 SS 患者和 72.3%的 MRCL 患者接受了≥2线的系统治疗。SS 患者一线治疗的中位 OS 和中位 PFS 分别为 24.7 个月（95%CI，20.9-29.4）和 7.5 个月（95%CI，6.4-8.4）。MRCL 患者从一线治疗开始的中位 OS 和中位 PFS 分别为 29.9 个月（95%CI，27-44.6）和 8.9 个月（95%CI 4.5-12.0）。
据我们所知，这是对 SS 和 MRCL 患者进行的最大规模的回顾性研究。它分析了在主要肉瘤癌症中心治疗的患者的真实临床结局，并为治疗决策和临床试验设计提供了信息。总的来说，这一选定人群的生存结果似乎比已发表文献中的更有利。
